will fda ban compounded semaglutide moves to remove GLP-1 medications from 503B Bulks List Fifth Circuit probes FDA ban

Triple-Incretin Agonism with Retatrutide in Severe Obesity: 104-Week Results of the Phase 3 TRIUMPH-1 Trial

Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial

Why Your Doctor Matters More, Not Less, in the GLP-1 Era The class of drugs retatrutide belongs to is rewriting how primary care manages obesity, diabetes, and metabolic disease

They are only a handful of known companies active on that space, but the excitement around them is a testimony of the appetite of agrifood companies for solutions to the rising challenge

Avoid caffeine, alcohol, and high-fiber foods until symptoms stabilize

In the 48-week phase 2 trial published in the New England Journal of Medicine, retatrutide at the 12mg weekly dose produced an average body weight reduction of 24.2%